Zentalis Pharmaceuticals develops azenosertib, an experimental oral cancer drug for ovarian cancer and other tumors. ZNTL reports earnings on Tue, Nov 10, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 19 | HC Wainwright & Co. | Reiterated | Buy | |
| Oct 5 | Leerink Partners | Assumed coverage | Buy | |
| Jul 23 | Rodman & Renshaw | Initiated | Buy | |
| Jul 17 | Mizuho | Initiated | Buy |
Seasonality
How ZNTL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in ZNTL in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ZNTL is in one of them and how their past ZNTL trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ZNTL in an article yet. Here's the latest on the wider market.
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals is a drug developer based in San Diego, California. Its main focus is azenosertib, an experimental oral medicine that works by blocking a cell protein called WEE1. The drug is being developed for patients with ovarian cancer and possibly other tumor types. The company is testing it in clinical trials, with its current focus on patients with platinum-resistant ovarian cancer whose tumors show high levels of Cyclin E1 protein.
- Headquarters
- San Diego, CA